Search

Displaying results 3891 - 3900 of 10000 in total
  1. Drug

    Roxithromycin

    go.drugbank.com/drugs/DB00778
    ApprovedInvestigationalWithdrawn

    It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections. … It was shown to be more effective against certain Gram-negative bacteria, particularly _Legionella pneumophila_.

    International brands: Le Er Tai, Ren Su
  2. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment. … [L63806,L63934] Established ADHD pharmacotherapy acts on norepinephrine and dopamine without a serotonergic component, and Otsuka describes centanafadine as the first and only approved norepinephrine-dopamine-serotonin

  3. Drug

    Sodium sulfide

    go.drugbank.com/drugs/DB11159
    Approved

    Interestingly, sodium sulfide was shown to have some cardioprotective role against cardiac ischemia or reperfusion injury, as well as protect lungs against ventilator-induced lung injury [A27275]. … H2S is an endogenous gaseous transmitter that exhibits anti-inflammatory and antiapoptotic properties.

  4. Drug

    Loteprednol

    go.drugbank.com/drugs/DB00873
    ApprovedInvestigationalWithdrawn

    Loteprednol is a corticosteroid. A more commonly used formulation of loteprednol is its ester, loteprednol etabonate.

  5. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    [L63795] Enlicitide is indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), and was studied in … [L63795] Enlicitide was developed by Merck Sharp & Dohme and received initial U.S. approval in 2026, marketed under the trade name LIPFENDRA.[L63795]

  6. Drug

    Ethylmorphine

    go.drugbank.com/drugs/DB01466
    IllicitInvestigational

    It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. … In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products).

  7. Drug

    L523S

    go.drugbank.com/drugs/DB06498
    Investigational

    According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) … [A175909] It has been investigated as a lung cancer vaccine.

  8. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    efficacy anti-IgE antibody therapy in the treatment of CSU has been previously established with omalizumab. … Similar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer

  9. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    It was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998] … in severe systemic copper deficiency.

  10. Drug

    ALKS 27

    go.drugbank.com/drugs/DB05752
    Experimental

    Study showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed. … ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD).